Clinical features and oncological outcomes of bladder cancer microsatellite instability
Shohei Nagakawa
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Masaki Shiota
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Correspondence
Masaki Shiota M.D., Ph.D., Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Email: [email protected]
Search for more papers by this authorDai Takamatsu
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorShigehiro Tsukahara
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakashi Mastumoto
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorLeandro Blas
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorJunichi Inokuchi
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorYoshihiro Oda
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorMasatoshi Eto
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorShohei Nagakawa
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Masaki Shiota
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Correspondence
Masaki Shiota M.D., Ph.D., Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Email: [email protected]
Search for more papers by this authorDai Takamatsu
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorShigehiro Tsukahara
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakashi Mastumoto
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorLeandro Blas
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorJunichi Inokuchi
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorYoshihiro Oda
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorMasatoshi Eto
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorAbstract
Objectives
Excellent anticancer effect for solid tumors with microsatellite instability (MSI)-high by anti-PD-1 antibody has been reported. In this study, we investigated the clinical impact of MSI status in bladder cancer.
Methods
This study included 205 Japanese patients who underwent transurethral resection for bladder cancer between 2005 and 2021. The prevalence rates of microsatellite stable (MSS), MSI-low (MSI-L), and MSI-high (MSI-H) were determined using molecular testing. We examined the association of MSI status (MSS versus MSI-L/H) with clinicopathological characteristics and oncological outcomes.
Results
MSI-L/H tumors were associated with higher T-category in non-muscle invasive bladder cancer (NMIBC). Additionally, MSI-L/H tumors were associated with a higher risk of intravesical recurrence in NMIBC patients treated with intravesical bacillus Calmette-Guérin (BCG) but not with non-BCG therapy.
Conclusions
This study suggested that the MSI status might serve as a predictive marker for intravesical recurrence after BCG intravesical therapy in NMIBC and highlighted an unmet need for an alternative treatment in patients with MSI-L/H tumors.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| iju15370-sup-0001-TableS1.xlsxExcel 2007 spreadsheet , 10.8 KB | Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017; 71: 96–108.
- 2Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol. 2019; 76: 639–657.
- 3Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016; 34: 1935–1944.
- 4Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466–475.
- 5Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859–866.
- 6 International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171–2177.
- 7Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008; 29: 673–680.
- 8Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509–2520.
- 9Burger M, Burger SJ, Denzinger S, Wild PJ, Wieland WF, Blaszyk H, et al. Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol. 2006; 50: 770–775.
- 10Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kähler C, Kluth M, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urol Oncol. 2020; 38: 488–495.
- 11Mongiat-Artus P, Miquel C, van der Aa M, Buhard O, Hamelin R, Bangma C, et al. Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients. Eur Urol. 2006; 49: 685–690.
- 12Tural D, Akar E, Baytekin HF, Canoglu D, Yilmaz M, Tugcu V. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy. J BUON. 2021; 26: 2117–2125.
- 13Giedl J, Schneckenpointner R, Filbeck T, Ruemmele P, Hofstaedter F, Burger M, et al. Low frequency of HNPCC-associated microsatellite instability and aberrant MMR protein expression in early-onset bladder cancer. Am J Clin Pathol. 2014; 142: 634–639.
- 14Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016; 22: 1342–1350.
- 15Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017; 8: 15180.
- 16Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res. 2019; 25: 7035–7045.
- 17Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol. 1998; 22: 1435–1448.
- 18Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken NJ: John Wiley & Sons Inc; 2009.
- 19Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182: 2195–2203.
- 20Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, et al. Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol. 2020; 27: 362–368.
- 21Moon C, Gordon M, Moon D, Reynolds T. Microsatellite instability analysis (MSA) for bladder cancer: past history and future directions. Int J Mol Sci. 2021; 22: 12864.
- 22Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248–5257.
- 23Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T. Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Sci. 2018; 109: 3411–3415.
- 24Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008; 10: 293–300.
- 25Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017; 28: 96–102.
- 26Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30: 1232–1243.
- 27Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003; 105: 484–490.
- 28Kohlruss M, Chakraborty S, Hapfelmeier A, Jesinghaus M, Slotta-Huspenina J, Novotny A, et al. Low microsatellite instability: a distinct instability type in gastric cancer? J Cancer Res Clin Oncol. 2023; 149: 17727–17737. https://doi.org/10.1007/s00432-023-05430-6
- 29Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol. 2005; 5: 2.
- 30Kim HS, Seo HK. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. Investig Clin Urol. 2021; 62: 361–377.
Citing Literature
